Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Preclinical Pharmacokinetic and Pharmacodynamic Data To Support Cefoxitin Nebulization for the Treatment of Mycobacterium abscessus.

Mehta S, Aranzana-Climent V, Rammaert B, Grégoire N, Marchand S, Couet W, Buyck JM.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e02651-18. doi: 10.1128/AAC.02651-18. Print 2019 Jul.

PMID:
31061149
2.

Quantitative contribution of efflux to multi-drug resistance of clinical Escherichia coli and Pseudomonas aeruginosa strains.

Cunrath O, Meinel DM, Maturana P, Fanous J, Buyck JM, Saint Auguste P, Seth-Smith HMB, Körner J, Dehio C, Trebosc V, Kemmer C, Neher R, Egli A, Bumann D.

EBioMedicine. 2019 Mar;41:479-487. doi: 10.1016/j.ebiom.2019.02.061. Epub 2019 Mar 7.

3.

Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in Pseudomonas aeruginosa by Distinct Mechanisms.

Anantharajah A, Buyck JM, Sundin C, Tulkens PM, Mingeot-Leclercq MP, Van Bambeke F.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02566-16. doi: 10.1128/AAC.02566-16. Print 2017 Jun.

4.

Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa.

Buyck JM, Luyckx C, Muccioli GG, Krause KM, Nichols WW, Tulkens PM, Van Bambeke F.

J Antimicrob Chemother. 2017 May 1;72(5):1400-1409. doi: 10.1093/jac/dkw587.

PMID:
28137941
5.

Inhibition of the Injectisome and Flagellar Type III Secretion Systems by INP1855 Impairs Pseudomonas aeruginosa Pathogenicity and Inflammasome Activation.

Anantharajah A, Faure E, Buyck JM, Sundin C, Lindmark T, Mecsas J, Yahr TL, Tulkens PM, Mingeot-Leclercq MP, Guery B, Van Bambeke F.

J Infect Dis. 2016 Oct 1;214(7):1105-16. doi: 10.1093/infdis/jiw295. Epub 2016 Jul 13.

PMID:
27412581
6.

In Vitro Models for the Study of the Intracellular Activity of Antibiotics.

Buyck JM, Lemaire S, Seral C, Anantharajah A, Peyrusson F, Tulkens PM, Van Bambeke F.

Methods Mol Biol. 2016;1333:147-57. doi: 10.1007/978-1-4939-2854-5_13.

PMID:
26468107
7.

Correlation between cytotoxicity induced by Pseudomonas aeruginosa clinical isolates from acute infections and IL-1β secretion in a model of human THP-1 monocytes.

Anantharajah A, Buyck JM, Faure E, Glupczynski Y, Rodriguez-Villalobos H, De Vos D, Pirnay JP, Bilocq F, Guery B, Tulkens PM, Mingeot-Leclercq MP, Van Bambeke F.

Pathog Dis. 2015 Oct;73(7). pii: ftv049. doi: 10.1093/femspd/ftv049. Epub 2015 Jul 22.

8.
9.

Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.

Buyck JM, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2015 Jan;59(1):258-68. doi: 10.1128/AAC.04011-14. Epub 2014 Oct 27.

10.

New amphiphilic neamine derivatives active against resistant Pseudomonas aeruginosa and their interactions with lipopolysaccharides.

Sautrey G, Zimmermann L, Deleu M, Delbar A, Souza Machado L, Jeannot K, Van Bambeke F, Buyck JM, Decout JL, Mingeot-Leclercq MP.

Antimicrob Agents Chemother. 2014 Aug;58(8):4420-30. doi: 10.1128/AAC.02536-13. Epub 2014 May 27.

11.

Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes.

Buyck JM, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2013 May;57(5):2310-8. doi: 10.1128/AAC.02609-12. Epub 2013 Mar 11.

12.

P. aeruginosa LPS stimulates calcium signaling and chloride secretion via CFTR in human bronchial epithelial cells.

Buyck JM, Verriere V, Benmahdi R, Higgins G, Guery B, Matran R, Harvey BJ, Faure K, Urbach V.

J Cyst Fibros. 2013 Jan;12(1):60-7. doi: 10.1016/j.jcf.2012.06.007. Epub 2012 Jul 17.

13.

Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability.

Buyck JM, Plésiat P, Traore H, Vanderbist F, Tulkens PM, Van Bambeke F.

Clin Infect Dis. 2012 Aug;55(4):534-42. doi: 10.1093/cid/cis473. Epub 2012 May 9.

PMID:
22573850
14.

Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis.

Buyck JM, Guénard S, Plésiat P, Tulkens PM, Van Bambeke F.

J Antimicrob Chemother. 2012 Mar;67(3):771-5. doi: 10.1093/jac/dkr543. Epub 2012 Jan 3. No abstract available.

PMID:
22218683

Supplemental Content

Loading ...
Support Center